- Home
- SLGB vs ALXO Comparison
SLGB vs ALXO Comparison
Compare SLGB & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | ALXO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 79.7M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLGB | ALXO |
|---|---|---|
| Price | $1.91 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 43.0K | ★ 274.6K |
| Earning Date | 12-23-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $92,917,774.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.74 | $0.40 |
| 52 Week High | $6.08 | $2.27 |
Technical Indicators
Market Signals| Indicator | SLGB | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.51 |
| Support Level | N/A | $1.29 |
| Resistance Level | N/A | $1.60 |
| Average True Range (ATR) | 0.00 | 0.13 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 58.70 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.